AngioDynamics, Inc. (NASDAQ: ANGO) is a Healthcare company in the Medical - Instruments & Supplies industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | - | EPS (ttm) | -0.88 | Insider Own | 7.02% | Shs Outstand | 41.33M | Perf Week | 6.09% |
| Market Cap | 648.51M | Forward P/E | - | EPS next Y | -0.04 | Insider Trans | -0.80% | Shs Float | 36.54M | Perf Month | 21.44% |
| Enterprise Value | 594.64M | PEG | 1.49 | EPS next Q | -0.09 | Inst Own | - | Short Float | 3.60% | Perf Quarter | 39.22% |
| Income | -36.58M | P/S | 2.03 | EPS this Y | 69.70% | Inst Trans | - | Short Ratio | 3.41 | Perf Half Y | 55.96% |
| Sales | 320.18M | P/B | 3.81 | EPS next Y | 83.13% | ROA | -13.75% | Short Interest | 1.32M | Perf YTD | 22.20% |
| Book/sh | - | P/C | - | EPS next 5Y | - | ROE | -21.01% | 52W High | 15.79 -0.25% | Perf Year | 86.79% |
| Cash/sh | - | P/FCF | - | EPS past 3/5Y | - | ROIC | -20.75% | 52W Low | 8.39 87.68% | Perf 3Y | 87.01% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | -1.90% 1.92% | Gross Margin | 54.62% | Volatility | 3.09% 4.50% | Perf 5Y | -41.08% |
| Dividend TTM | - | EV/Sales | 1.86 | EPS Y/Y TTM | -6.02% | Oper. Margin | -12.47% | ATR (14) | 0.54 | Perf 10Y | -5.02% |
| Dividend Ex-Date | - | Quick Ratio | 1.49 | Sales Y/Y TTM | 9.59% | Profit Margin | -11.48% | RSI (14) | 72.47 | Recom | 2.55 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.19 | EPS Q/Q | - | SMA20 | 10.08% | Beta | 0.31 | Target Price | 19.50 |
| Payout | 0.00% | Debt/Eq | 0.00 | Sales Q/Q | 8.75% | SMA50 | 19.61% | Rel Volume | 0.94 | Prev Close | 15.69 |
| Employees | 632 | LT Debt/Eq | 0.04 | Earnings | Oct 01 | SMA200 | 32.23% | Avg Volume | 431.38K | Price | 15.75 |
| IPO Date | Jun 01, 2004 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 21.96% 7.93% | Net Debt/EBITDA | 1.50 | Volume | 405,873 | Change | 0.38% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jul-15-26 | Reiterated | HC Wainwright & Co. | Buy | $14 → $19 |
| Jul-15-26 | Reiterated | Canaccord Genuity | Buy | $18 → $20 |
| Oct-03-25 | Reiterated | Canaccord Genuity | Buy | $17 → $18 |
| Jul-16-25 | Reiterated | Canaccord Genuity | Buy | $12 → $17 |
| Oct-04-24 | Reiterated | Canaccord Genuity | Buy | $12 |
| Sep-20-24 | Reiterated | HC Wainwright & Co. | Buy | $14 |
| Apr-05-24 | Upgrade | Oppenheimer | Perform → Outperform | $12 |
| Apr-17-23 | Downgrade | Raymond James | Strong Buy → Outperform | |
| Jan-06-23 | Reiterated | Raymond James | Strong Buy | $27 → $22 |
| Jul-13-22 | Reiterated | Raymond James | Strong Buy | $27 |
AngioDynamics, Inc. specializes in the development, manufacturing, and commercialization of a diverse array of medical, surgical, and diagnostic instruments. These products are utilized by healthcare professionals to address conditions such as peripheral vascular disease, facilitate vascular access, and support various oncology and surgical interventions, serving both domestic and international markets. The company's portfolio includes advanced ablation systems like NanoKnife, designed for the precise surgical removal of soft tissues, and Solero microwave and radiofrequency systems, effective in ablating solid cancerous or benign growths. Additionally, they provide BioSentry tract sealant systems, IsoLoc Endorectal Balloons, Alatus vaginal balloon packing systems, angiographic catheters, guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits. Their endovascular therapies segment encompasses solutions for thrombus management, atherectomy procedures, core peripheral products, and the treatment of venous insufficiency. Furthermore, AngioDynamics is a key supplier of vascular access devices, such as peripherally inserted central catheters (PICCs), midline catheters, implantable ports, and dialysis catheters, along with associated accessories. These are primarily employed for short-duration systemic drug delivery, including chemotherapy and antibiotics, marketed under a robust portfolio of brand names such as BioFlo, BioFlo Midline, BioFlo PICC, Xcela PICC, PASV, BioFlo Port, SmartPort, Vortex, LifeGuard, BioFlo DuraMax, and DuraMax. The company distributes its offerings directly to a specialized clientele, including interventional radiologists, cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses, while also leveraging established distributor networks. Founded in 1988, AngioDynamics maintains its corporate headquarters in Latham, New York.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2026 5/31/2026 | FY 2025 5/31/2025 | FY 2024 5/31/2024 | FY 2023 5/31/2023 | FY 2022 5/31/2022 | FY 2021 5/31/2021 | FY 2020 5/31/2020 | FY 2019 5/31/2019 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 320 | 320 | 292 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 145 | 145 | 135 | — | — | — | — | — | — | |
| Gross Profit | 174 | 175 | 158 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 157 | 157 | 145 | — | — | — | — | — | — | |
| Research and Development | 29 | 29 | 26 | — | — | — | — | — | — | |
| Other Operating Expense | 30 | 29 | 27 | — | — | — | — | — | — | |
| Operating Income | -39 | -40 | -40 | — | — | — | — | — | — | |
| Interest Expense | 0 | 0 | 0 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 3 | 4 | 6 | — | — | — | — | — | — | |
| Net Income Before Taxes | -36 | -36 | -34 | — | — | — | — | — | — | |
| Income Taxes | 0 | 0 | 0 | — | — | — | — | — | — | |
| Consolidated Net Income | -36 | -37 | -34 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | -36 | -37 | -34 | — | — | — | — | — | — | |
| Net Income | -36 | -37 | -34 | — | — | — | — | — | — | |
| EPS (Recurring) | -0.88 | -0.88 | -0.83 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -0.88 | -0.88 | -0.83 | — | — | — | — | — | — | |
| EPS (Diluted) | -0.88 | -0.88 | -0.83 | — | — | — | — | — | — | |
| EBITDA | -35 | -36 | 2 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 2.07 | 1.51 | 1.43 | — | — | — | — | — | — | |
| Gross Margin | 54.37 | 54.69 | 54.11 | — | — | — | — | — | — | |
| Operating Margin | -12.19 | -12.50 | -13.70 | — | — | — | — | — | — | |
| Net Margin | -11.25 | -11.56 | -11.64 | — | — | — | — | — | — | |
| Shares Outstanding | 42 | 42 | 41 | — | — | — | — | — | — | |
| Market Capitalization | 662 | 482 | 418 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Nighan Warren JR | SVP Quality and Regulatory | Jul 30 '26 | Sale | 14.72 | 23,370 | 344,006 | 64,745 | Jul 31 |
| Nighan Warren JR | SVP Quality and Regulatory | Jul 22 '26 | Option Exercise | 0.00 | 25,746 | 0 | 89,786 | Jul 24 |
| Trowbridge Stephen A | EVP and CFO | Jul 22 '26 | Option Exercise | 0.00 | 73,677 | 0 | 314,115 | Jul 24 |
| Clemmer James C | President and CEO | Jul 22 '26 | Option Exercise | 0.00 | 236,719 | 0 | 889,176 | Jul 24 |
| Campbell Chad Thomas | SVP/GM, Vascular Access | Jul 22 '26 | Option Exercise | 0.00 | 29,234 | 0 | 111,006 | Jul 24 |
| Piccinini Laura | SVP International | Jul 22 '26 | Option Exercise | 0.00 | 36,383 | 0 | 86,435 | Jul 24 |
| Weiss Lawrence T | SVP, Chief Legal Officer | Oct 21 '25 | Buy | 11.81 | 10,000 | 118,100 | 93,597 | Oct 22 |
| Trowbridge Stephen A | EVP and CFO | Oct 13 '25 | Buy | 11.16 | 890 | 9,932 | 256,629 | Oct 14 |
| Clemmer James C | President and CEO | Oct 09 '25 | Buy | 11.15 | 10,000 | 111,500 | 882,529 | Oct 09 |
| Nighan Warren JR | SVP Quality and Regulatory | Jan 16 '25 | Sale | 12.31 | 4,060 | 49,979 | 41,817 | Jan 17 |
| Nighan Warren JR | SVP Quality and Regulatory | Oct 10 '24 | Buy | 6.08 | 100 | 608 | 45,877 | Oct 10 |
| Nighan Warren JR | SVP Quality and Regulatory | Oct 07 '24 | Buy | 6.09 | 768 | 4,677 | 45,777 | Oct 10 |
| Trowbridge Stephen A | EVP and CFO | Oct 08 '24 | Buy | 5.86 | 1,700 | 9,962 | 172,711 | Oct 08 |
| Clemmer James C | President and CEO | Oct 07 '24 | Buy | 6.03 | 20,000 | 120,600 | 681,582 | Oct 08 |
| Clemmer James C | President and CEO | Jul 17 '24 | Option Exercise | 0.00 | 108,657 | 0 | 690,312 | Aug 02 |